3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
13
NIH
8
NETWORK
1
INDUSTRY
1
INDIV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
5
Glioblastoma
4
Breast Neoplasms
4
Melanoma
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Glioma
1
Breast Neoplasms, Male
1
Brain Neoplasms
1
Advanced Ovarian Cancer
1
Advanced Cancer
1
Interventions
Prednisone
102
enzalutamide
74
Docetaxel
72
Abiraterone Acetate
67
Leuprolide
47
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
45
abiraterone
37
apalutamide
28
Prednisolone
27
bicalutamide
26
Zoledronic Acid
24
pembrolizumab
22
Goserelin
22
radium Ra 223 dichloride
21
darolutamide
21
Triptorelin Pamoate
17
cabazitaxel
15
Androgen Antagonists
15
sipuleucel-T
13
luprolide acetate gel depot
12
Injections
12
Dexamethasone
12
olaparib
11
gallium 68 PSMA-11
10
Mitoxantrone
10
Pluvicto
9
Ipilimumab
9
Dutasteride
9
Cyclophosphamide
9
relugolix
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms
×
sargramostim
×
Clear all
NCT01784913
2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2
Completed
22 enrolled